Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZOPT vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Open-angle glaucoma,Ocular hypertension
Relief of moderate to moderately severe pain
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 m L/min).
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Not significantly metabolized; primarily excreted unchanged in urine via renal tubular secretion.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Approximately 33% bound to plasma proteins (mainly albumin).
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.35 L/kg, indicating distribution primarily into extracellular fluid.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Ocular bioavailability is not quantified due to local administration; systemic bioavailability after topical ocular dosing is approximately 70% via nasolacrimal absorption.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
No dosage adjustment required for systemic absorption is minimal. However, use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential metabolite accumulation.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
No dosage adjustment required for systemic absorption is minimal. Use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Approved for children ≥2 years: one drop in the affected eye(s) twice daily. For children <2 years: safety and efficacy not established.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
No specific dose adjustment required. Monitor for ocular irritation and systemic effects, as elderly patients may be more sensitive to adverse reactions such as hypotension or fatigue.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
None
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Sulfonamide allergy (cross-reactivity possible),Corneal endothelial damage (risk increased with low endothelial cell count),Bacterial keratitis (with concomitant use of topical corticosteroids or ocular trauma),Contaminated dropper tip may cause ocular infections
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Hypersensitivity to brinzolamide or any sulfonamides,Severe renal impairment (Cr Cl <30 m L/min) or hyperchloremic acidosis
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
No significant food interactions known. However, avoid excessive salt intake if using systemic carbonic anhydrase inhibitors; for AZOPT, ocular use minimizes systemic effects, but caution in patients with electrolyte imbalances.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in rabbits and 20 mg/kg/day in rats. However, due to potential for fetal harm (systemic carbonic anhydrase inhibition causing acidosis), use only if clearly needed. First trimester: avoid if possible; second/third trimesters: monitor for maternal acidosis.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
It is not known if brinzolamide is excreted in human milk. In animal studies, brinzolamide was detected in milk of lactating rats. Caution is advised; consider risk vs benefit. M/P ratio: unknown.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No specific dose adjustments recommended; however, due to potential for increased systemic absorption during pregnancy (increased blood volume and ocular changes), monitor intraocular pressure closely. Use the lowest effective dose. Pharmacokinetic changes: unknown; adjust based on clinical response.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
AZOPT (brinzolamide ophthalmic suspension) is a carbonic anhydrase inhibitor used for lowering intraocular pressure in ocular hypertension or open-angle glaucoma. Shake well before use; may cause transient blurred vision. Use with caution in sulfonamide allergy patients. Monitor for corneal edema and electrolyte disturbances in prolonged use.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Shake the bottle vigorously before each use.,Remove contact lenses before instilling and wait at least 15 minutes before reinserting.,Apply pressure to the tear duct (punctal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,May cause temporary blurred vision; avoid driving or operating machinery until vision clears.,Report any eye pain, redness, or vision changes to your healthcare provider.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZOPT vs ANEXSIA, answered by our medical review team.
AZOPT is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZOPT and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZOPT is: One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZOPT and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZOPT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in ra. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.